September 09, 2024

EASD: Monthly Semaglutide Injection Shows Promise

A novel once-a-month injectable showed regular drug release over a 1-month period with limited burst in a rat study.

August 09, 2024

Gestational Diabetes and Risk for Breast Cancer

Investigators examined whether women who develop gestational diabetes may have a higher likelihood of being diagnosed with breast cancer, according to findings that will be presented at the upcoming E...

September 09, 2024

EASD: Childhood Diet Linked to Type 1 Diabetes Risk

A new study finds childhood consumption of berries linked to lower type 1 diabetes risk, while fruit and oats associated with higher risk.

September 09, 2024

EASD: Sleep Timing Linked to Fat Distribution, Diabetes

New study reveals night owls may have a 46% higher risk for type 2 diabetes, with increased ectopic fat deposition a potential culprit.

September 09, 2024

Higher BMI Linked to Severe Infection Risk

Study finds a 30% higher bacterial infection risk per each 5-point increase in BMI.

August 28, 2024

Can a Blood Test Predict Obesity-Related Cancer Risk in Patients With Type 2 Diabetes?

Researchers explored whether measuring proinflammatory cytokine levels could effectively identify patients with type 2 diabetes who may be at a higher risk of developing certain cancers. Their finding...

September 10, 2024

EASD: Diabetes-Asthma May Share Bidirectional Link

Patients with type 2 diabetes may face an 83% higher risk of developing asthma, while patients with asthma are 28% more likely to develop diabetes, revealing a bidirectional relationship.

September 19, 2024

Steroid Use Doubled Diabetes Risk in UK Study

UK study of 451,606 hospitalized patients reveals systemic glucocorticoid use associated with 2.6-fold increased risk of new-onset diabetes, with incidence rates of 51.9 vs 18.5 per 100 person-years in exposed vs unexposed groups.

September 09, 2024

EASD: Insulin Resistance Tied to 31 Diseases

For each unit increase in insulin resistance, the risk of pancreatitis rose by 31%, the risk of sleep disorders by 18%, and the risk of bacterial infections by 8%.

September 11, 2024

EASD: Liraglutide Shows Efficacy for Childhood Obesity Treatment

The randomized, phase 3 SCALE Kids trial found that liraglutide dosed at 3.0 mg reduced BMI in children aged 6 to <12 years with obesity.